Skip to main content

Table 3 Acute adverse events recorded during concurrent high-dose intensity-modulated radiation therapy and docetaxel-based chemotherapy: blood/bone marrow

From: Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial

 

Grade

Anemia

Leucopenia

Neutropenia

Thrombocytopenia

Highest

Cohort 1

1

5

6

3

1

6

2

1

3

0

0

3

3

0

1

0

0

1

Cohort 2

1

6

5

2

1

5

2

2

4

1

0

4

 

3

0

0

0

0

0